Oncternal Therapeutics Inc logo

Oncternal Therapeutics Inc

FRA:GTU (USA)  
€ 5.32 (0%) Mar 27
At Loss
P/B:
0.80
Market Cap:
€ 22.41M ($ 24.17M)
Enterprise V:
€ -8.93M ($ -9.63M)
Volume:
-
Avg Vol (2M):
-
Also Trade In:

Business Description

Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 107.72
Equity-to-Asset 0.82
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 24.77
9-Day RSI 34.59
14-Day RSI 40.59
6-1 Month Momentum % 8.13
12-1 Month Momentum % -61.26

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.94
Quick Ratio 6.94
Cash Ratio 6.59

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -6.5
Shareholder Yield % -5.1

Financials (Next Earnings Date:2024-05-03 Est.)

FRA:GTU's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Oncternal Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -12.47
Beta 0.77
Volatility % 100.28
14-Day RSI 40.59
14-Day ATR (€) 0.016544
20-Day SMA (€) 5.32
12-1 Month Momentum % -61.26
52-Week Range (€) 4.04 - 14.388
Shares Outstanding (Mil) 2.96

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Oncternal Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Oncternal Therapeutics Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Oncternal Therapeutics Inc Frequently Asked Questions

What is Oncternal Therapeutics Inc(FRA:GTU)'s stock price today?
The current price of FRA:GTU is €5.32. The 52 week high of FRA:GTU is €14.39 and 52 week low is €4.04.
When is next earnings date of Oncternal Therapeutics Inc(FRA:GTU)?
The next earnings date of Oncternal Therapeutics Inc(FRA:GTU) is 2024-05-03 Est..
Does Oncternal Therapeutics Inc(FRA:GTU) pay dividends? If so, how much?
Oncternal Therapeutics Inc(FRA:GTU) does not pay dividend.

Press Release

Subject Date
No Press Release